Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl‑2

Abstract

Oridonin is an active component of the traditional Chinese herb Rabdosia rubescens. The present study aimed to evaluate the antitumor effects of oridonin on human non-small cell lung cancer (NSCLC) cells and explore whether oridonin could enhance their radiosensitivity. Oridonin was demonstrated to inhibit the proliferation of SPC-A-1 and HCC827 lung cancer cells in a time-and dose-dependent manner, which was detected using the MTT assay. In addition, pretreatment with oridonin for 24 h prior to irradiation was identified to enhance the radiosensitivity of SPC-A-1 cells. Furthermore, the levels of apoptosis regulator BAX (Bax) and apoptosis regulator Bcl-2 (Bcl-2) were detected by western blotting analysis. The results demonstrated that the level of Bax was increased and the level of Bcl-2 was decreased in SPC-A-1 cells treated with oridonin and irradiation compared with the group that received irradiation alone. These results indicate that oridonin may have a novel application as a radiosensitizing agent for the treatment of human NSCLC.

Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier

“…Molecules 2019, 24, x 2 of 18 Oridonin (ORI) is an active diterpenoid extracted from the Chinese medicinal herb Rabdosia rubescens [3,4] that exhibits potential anticancer, antiinflammation, and antibacterial effects [5,6]. Its chemical structure is shown in Figure 1.…”

ThermomiR-377-3p-induced Suppression of Cirbp Expression Is Required for Effective Elimination of Cancer Cells and Cancer Stem-like Cells by Hyperthermia

“…Natural product Ori is the major active ingredient of the traditional Chinese medicinal herb Rabdosia rubescens, and has anti-tumor activity [58][59][60][61][62][63][64][65][66][67][68][69][70][71][72] and anti-in ammatory [131]. Ori and its analogue alone or combined with chemotherapy and radiotherapy was reported to effectively kill tumor cells of leukemia, ovarian cancer, lung cancer, esophageal squamous cell carcinoma, osteosarcoma, breast cancer, colorectal cancer and prostate cancer [58][59][60][61][62][63][64][65][66][67][68][69][70][71][72]. As CSCs have been identi ed as the main center of cancer therapeutic resistance [132][133][134], eradicating CSCs is considered as an effective and powerful strategy to improve current anti-cancer therapeutics [132][133][134].…”

“…Natural product oridonin (Ori) and its analogue alone or combined with chemotherapy and radiotherapy were reported to effectively kill tumor cells of leukemia, ovarian cancer, lung cancer, esophageal squamous cell carcinoma, osteosarcoma, breast cancer, colorectal cancer and prostate cancer [58][59][60][61][62][63][64][65][66][67][68][69][70][71][72]. To explore whether combination treatment of hyperthermia and Ori could signi cantly enhance the cell-killing effect on NPC cells and stem-like cancer cells, we rst evaluated the effects of the different concentrations of Ori on cell viability.…”

Solubility and Bioavailability Enhancement of Oridonin: A Review

“…ORI also has anti-bacterial [5], anti-inflammation [6], anti-oxidation [7], depressurization [8], anti-inflammation [9][10][11], immune-modulating [12] and analgesia [13] effects (Table 1). In particular, ORI demonstrates a significant inhibitory effect on the proliferation of more than 20 human cancer cell lines, such as common esophageal cancer [14], lung cancer [15], liver cancer [16], prostate cancer [17], breast cancer [18], and colorectal cancer [19], which is attributed to its specific molecular structure. The α-methylene cyclopentanone (enone) on the D-ring is the essential structure of the anti-cancer activity, which can be impaired by ring splitting or methylene saturation [20].…”